{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:36:27Z","timestamp":1792712187345,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00520-025-09210-5","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:11:45Z","timestamp":1738703505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: analysis based on real-world data"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-9822","authenticated-orcid":false,"given":"Hiroshi","family":"Inano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1058-0614","authenticated-orcid":false,"given":"Yoshihito","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanata","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Anzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"9210_CR1","doi-asserted-by":"publisher","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, CINV Study Group of Japan (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865.https:\/\/doi.org\/10.1007\/s10147-015-0786-7","DOI":"10.1007\/s10147-015-0786-7"},{"key":"9210_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Iihara H, Ohtani S, Okuyama A, Ozawa K, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Higashi T, Hirata K (2021) Optimizing antiemetic treatment for chemotherapy induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"9210_CR3","doi-asserted-by":"publisher","first-page":"e015645","DOI":"10.1136\/bmjopen-2016-015645","volume":"7","author":"U Restelli","year":"2017","unstructured":"Restelli U, Saibene G, Nardulli P, Di Turi R, Bonizzoni E, Scolari F, Perrone T, Croce D, Celio L (2017) Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open 7:e015645. https:\/\/doi.org\/10.1136\/bmjopen-2016-015645","journal-title":"BMJ Open"},{"key":"9210_CR4","doi-asserted-by":"publisher","first-page":"212298","DOI":"10.7573\/dic.212298","volume":"6","author":"H Cawston","year":"2017","unstructured":"Cawston H, Bourhis F, Eriksson J, Ruffo P, D\u2019Agostino P, Turini M, Schwartzberg L, McGuire A (2017) NEPA, a new fixed combination of netupitant and palonosetron is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context 6:212298. https:\/\/doi.org\/10.7573\/dic.212298","journal-title":"Drugs Context"},{"key":"9210_CR5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00520-019-04824-y","volume":"28","author":"M Botteman","year":"2020","unstructured":"Botteman M, Nickel K, Corman S, Turini M, Binder G (2020) Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. Support Care Cancer 28:857\u2013866. https:\/\/doi.org\/10.1007\/s00520-019-04824-y","journal-title":"Support Care Cancer"},{"key":"9210_CR6","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.1007\/s00520-022-07339-1","volume":"30","author":"J Nilsson","year":"2022","unstructured":"Nilsson J, Piovesana V, Turini M, Lezzi C, Eriksson J, Aapro M (2022) Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer 30:9307\u20139315. https:\/\/doi.org\/10.1007\/s00520-022-07339-1","journal-title":"Support Care Cancer"},{"key":"9210_CR7","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/cas.13736","volume":"109","author":"I Tsukiyama","year":"2018","unstructured":"Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y, Ejiri M, Sakuma M, Saito H, Arakawa I, Inoue T, Yamaguchi E, Kubo A (2018) Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci 109:2881\u20132888. https:\/\/doi.org\/10.1111\/cas.13736","journal-title":"Cancer Sci"},{"key":"9210_CR8","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1007\/s00520-019-04672-w","volume":"27","author":"I Tsukiyama","year":"2019","unstructured":"Tsukiyama I, Ando M, Tsukiyama S, Takeuchi M, Ejiri M, Kurose Y, Saito H, Arakawa I, Inoue T, Yamaguchi E, Kubo A (2019) Cost-utility analysis of aprepitant for patients who truly need it in Japan. Support Care Cancer 27:3749\u20133758. https:\/\/doi.org\/10.1007\/s00520-019-04672-w","journal-title":"Support Care Cancer"},{"key":"9210_CR9","first-page":"95","volume":"42","author":"N Nakagawa","year":"2018","unstructured":"Nakagawa N, Watanabe Y, Kikuchi M, Ishida T, Kisara S, Lai L (2018) A cost-effectiveness analysis of neurokinin 1 receptor antagonists for the FEC100 regimen in breast cancer. J Drug Interact Res 42:95\u2013102","journal-title":"J Drug Interact Res"},{"key":"9210_CR10","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.clinthera.2019.03.011","volume":"41","author":"M Kashiwa","year":"2019","unstructured":"Kashiwa M, Matsushita R (2019) Comparative cost-utility analysis between aprepitant- and fosaprepitant-containing regimens to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan. Clin Ther 41:929\u2013942. https:\/\/doi.org\/10.1016\/j.clinthera.2019.03.011","journal-title":"Clin Ther"},{"key":"9210_CR11","doi-asserted-by":"publisher","unstructured":"Hata A, Okamoto I, Inui N, Okada M, MD, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T (2022) Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40:180\u2013188https:\/\/doi.org\/10.1200\/JCO.21.01315","DOI":"10.1200\/JCO.21.01315"},{"key":"9210_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7150\/jca.7706","volume":"5","author":"Y Sato","year":"2014","unstructured":"Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, Yoshida T, Mori Y, Sawada H, Watanabe S, Sugiura H, Endo Y, Yoshimoto N, Toyama T, Iida S, Yamada K, Kimura K, Wakita A (2014) Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer 5:390\u2013397. https:\/\/doi.org\/10.7150\/jca.7706","journal-title":"J Cancer"},{"key":"9210_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1248\/bpb.b23-00819","volume":"47","author":"H Inano","year":"2024","unstructured":"Inano H, Morimoto Y, Kitagawa K, Shibuya A, Nakagomi K, Ota T, Anzo Y, Miyauchi R, Shono A, Watanabe K, Otori K (2024) Comparing the efficacy of fosnetupitant an NK1 receptor antagonist in CDDP-based regimens, with that of fosaprepitant and aprepitant: a retrospective observational study. Biol Pharm Bull 47:692\u2013697. https:\/\/doi.org\/10.1248\/bpb.b23-00819","journal-title":"Biol Pharm Bull"},{"key":"9210_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S44539","volume":"5","author":"S Humphreys","year":"2013","unstructured":"Humphreys S, Pellissier J, Jones A (2013) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res 5:215\u2013224. https:\/\/doi.org\/10.2147\/CMAR.S44539","journal-title":"Cancer Manag Res"},{"key":"9210_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.34088","volume":"128","author":"K Matsuura","year":"2022","unstructured":"Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K, Tamura T, Saeki T (2022) A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer 128:1692\u20131698. https:\/\/doi.org\/10.1002\/cncr.34088","journal-title":"Cancer"},{"key":"9210_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219\u2013227. https:\/\/doi.org\/10.1007\/s00520-004-0710-6","journal-title":"Support Care Cancer"},{"key":"9210_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10198-010-0224-8","volume":"12","author":"KS Boye","year":"2011","unstructured":"Boye KS, Matza LS, Walter KN, Van Brunt KV, Palsgrove AC, Tynan A (2011) Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ 12:219\u2013230. https:\/\/doi.org\/10.1007\/s10198-010-0224-8","journal-title":"Eur J Health Econ"},{"key":"9210_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19:422\u2013437. https:\/\/doi.org\/10.1002\/hec.1481","journal-title":"Health Econ"},{"key":"9210_CR19","unstructured":"Ministry of Health, Labour and Welfare (2023) Medias. https:\/\/www.mhlw.go.jp\/topics\/medias\/year\/22\/dl\/iryouhi_data_sankou.pdf. Accessed 19 Mar 2024 (in Japanese)"},{"key":"9210_CR20","doi-asserted-by":"publisher","first-page":"4928","DOI":"10.1007\/s12325-023-02648-1","volume":"40","author":"N Inui","year":"2023","unstructured":"Inui N, Toi Y, Yoneshima Y, Morise M, Hata A, Kubota K, Saeki T, Tamura T (2023) Pooled analysis of studies evaluating fosnetupitant and risk factors for cisplatin-induced nausea and vomiting during the extended overall phase. Adv Ther 40:4928\u20134944. https:\/\/doi.org\/10.1007\/s12325-023-02648-1","journal-title":"Adv Ther"},{"key":"9210_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-7547-11-22","volume":"11","author":"T Shiroiwa","year":"2013","unstructured":"Shiroiwa T, Igarashi A, Fukuda T, Ikeda S (2013) WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc 11:22. https:\/\/doi.org\/10.1186\/1478-7547-11-22","journal-title":"Cost Eff Resour Alloc"},{"key":"9210_CR22","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/13696998.2019.1639186","volume":"22","author":"A Igarashi","year":"2019","unstructured":"Igarashi A, Goto R, Yoneyama-Hirozane MY (2019) Willingness to pay for QALY: perspectives and contexts in Japan. J Med Econ 22:1041\u20131046. https:\/\/doi.org\/10.1080\/13696998.2019.1639186","journal-title":"J Med Econ"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09210-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09210-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09210-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:41:10Z","timestamp":1739511670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09210-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["9210"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09210-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Kitasato University Hospital (Approval No. B22-231) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given that this was a retrospective study, and all data were collected retrospectively from electronic medical records, the requirement for informed consent was waived. However, we also offered participants the opportunity to opt out of the use of their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}